Derya Unutmaz
Unutmaz’s longevity impact is real but narrow: he studies how immunity changes with age, from T-cell regulation to lifespan immune maps. No evidence here for field-building or capital deployment.
Role
scientisthigh confidence
The evidence shows authored research papers, including a peer-reviewed Immunity paper, and his longevity contribution is framed as aging/immunology research rather than title-only prestige. If you remove the science, most of the longevity footprint here disappears.
also: self-experimenter
Dimension breakdown
This score rates longevity commitment only. The role tags above — scientist, investor, and the rest — say what this person is; we don't score those separately.
Evidence is still sparse for this hero. Scores are shown with low-confidence warnings until more source material is harvested.
Future vision
3.0/ 10
There is some evidence of a public future-oriented stance around longevity, AI, and systems-based geroscience, but it is not a concrete or durable vision for ending aging, reversing biological decline, or materially extending healthy lifespan. The strongest evidence is a broad multidisciplinary geroscience framing rather than a specific longevity roadmap, theory, timeline, or destination.
low confidence
Scientific impact
4.0/ 10
Scientific impact applies, but the provided evidence lacks the rubric's primary signal: citation metrics. The available primary papers show credible immunology and aging-immunity research contributions, including a mechanistic Immunity paper and a recent lifespan single-cell immune atlas preprint, but there is no evidence here of citation weight, field-defining influence, clinical translation, or sustained agenda-setting impact.
low confidence
Capital deployed
N/A
The provided evidence supports Derya Unutmaz as an immunology/aging researcher, but contains no credible capital deployment activity to score. Structured facts explicitly report no investments or donations found and no disclosed totals.
Pure scientist profile with no evidence of personal capital, philanthropy, fund allocation, or institution-building resources deployed toward longevity.
medium confidence
Strategic taste
2.0/ 10
Strategic taste applies because the dimension can cover a scientist's research direction, but the provided evidence is thin. The strongest signal is a coherent public thesis around aging immunity, immunology, biomedical engineering, BioAI, and AI-enabled biology. However, there is no documented early, contrarian, counterfactually important bet, no founded program or deployment path, and no evidence that his choices opened paths others were not seeing. The score is therefore low despite plausible thesis coherence.
low confidence
Field creation
1.0/ 10
The dimension is applicable, but the provided evidence shows no founded organizations, programs, funding paths, protocols, or community-building activity attributable to Derya Unutmaz. The evidence only supports participation in aging/immunology research and collaborative publications, which is not enough to establish field-creation impact.
medium confidence
Bravery and conviction
2.0/ 10
The dimension applies, but evidence for bravery/conviction is very thin. The only direct signal is public self-identification as a biohacker with an explicit longevity affiliation, which shows some personal visibility around longevity-adjacent work but not documented risk, sacrifice, contrarian advocacy, criticism endured, or actual self-experimentation protocol.
low confidence
Multiplier effect
2.0/ 10
Multiplier effect applies, but the provided evidence shows only ordinary academic participation and a self-published public profile, not clear second-order leverage such as founding organizations, attracting capital, policy influence, talent pipelines, public legitimacy, or follow-on projects beyond direct research.
low confidence
Vision
Destination
Unutmaz envisions restoring 80- or 100-year-olds to the biology of their 20s,
restoring 80- or 100-year-olds to the biology of their 20s
With AI accelerating biomedical research, Unutmaz envisions restoring 80- or 100-year-olds to the biology of their 20s, calling it one of humanity’s most profound scientific frontiers.
restoring 80- or 100-year-olds to the biology of their 20s
Unutmaz envisions restoring 80- or 100-year-olds to the biology of their 20s,
With AI accelerating biomedical research, Unutmaz envisions restoring 80- or 100-year-olds to the biology of their 20s, calling it one of humanity’s most profound scientific frontiers.
With AI accelerating biomedical research, Unutmaz envisions restoring 80- or 100-year-olds to the biology of their 20s,
the first time in human history we have the possibility of reversing aging process. We will reverse aging. We will take 80 year old, 100 year old person will bring it back to a 20 year old
Now pioneering the integration of AI with longevity science, he predicts AI-accelerated interventions could reverse biological aging within a decade.
We will take 80 year old, 100 year old person will bring it back to a 20 year old I, I think.
he’s pioneering the use of AI to reverse biological aging and predicts interventions within the next decade could restore an 80-year-old’s vitality to their 20s.
he’s spent three decades decoding the human immune system—and now predicts that AI-accelerated interventions could restore an 80-year-old’s vitality to their 20s within the next decade.
Path
No canonical quotes yet.
Strategy
Advance longevity through aging-immunity research at the intersection of immunology, biomedical engineering, BioAI, and AI-enabled biology.
Derya Unutmaz’s supported strategy centers on immunology and aging-related biology, with longevity explicitly named as a focus area in his public profile [S1]. His profile also links this work to biomedical engineering, BioAI, and an "all in on AI" orientation, suggesting an AI-enabled biological research strategy rather than a documented investment or philanthropy strategy [S1]. No investments, donations, founded organizations, collaborators, or lineage relationships are supported by the provided evidence. Geographic focus is limited to Connecticut, USA, based only on the profile location [S1]. Stage preference, risk appetite, and time horizon are unknown from the available evidence.
UnknownUnknownImmunologyAging ImmunityLongevityBioAIBiomedical EngineeringConnecticut
Portfolio
Investments
Donations
No public rows yet.
Organizations founded
No public rows yet.
Scientific output
h-index-
Citations-
Papers5
Trials0
Bravery and conviction
Self-experimentation
Criticisms